ReviewInternational journal of clinical oncology2025
Escalation and de-escalation in surgery for gastric cancer.
Review in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Surgical resection remains the cornerstone of curative treatment for gastric cancer, providing effective local control. Recent advances in systemic therapies and the development of various surgical technologies have significantly transformed treatment strategies for this disease. Multiple clinical trials of gastric cancer surgery have demonstrated that extended surgical procedures do not improve survival outcomes, whereas minimally invasive approaches-such as conventional laparoscopic and robot-assisted surgeries-, have been shown to offer favorable safety and efficacy. Moreover, with an aging patient population and substantial progress in multidisciplinary treatments, including immunotherapy, the role of surgery is being reassessed, even for patient groups deemed unsuitable for surgical intervention, such as older patients and those with initially unresectable advanced gastric cancer. Furthermore, the introduction of novel diagnostic technologies has expanded the potential for individualized surgical decision-making by enabling more precise assessment of residual diseases. This review examines the current evidence and future perspectives on gastric cancer surgery, focusing on surgical escalation and de-escalation. Four key aspects are addressed: (1) surgical approach, (2) extent of lymphadenectomy, (3) extent of resection, and (4) surgical indications. These insights aim to inform optimal surgical strategies for gastric cancer in the era of evolving treatment paradigms.
Indexed as
Identifiers
40591222What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.